SIDLEY AUSTIN LLP

Lobbying for KARYOPHARM THERAPEUTICS · Pharmaceutical manufacturer

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Massachusetts · House · Senate · $100,000.00 income · posted Jan 20, 2026

Lobbying activity 1

Health Issues

Rare disease policy, drug approval process

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem